Neurodawn Pharmaceutical Co., Ltd.
Neurodawn Pharmaceutical Co., Ltd.
Explore linked clinical trials.10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Early phase 1 | 2026-08-17 | NCT07767370 | |
| Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction | PAI; Perforating Artery Infarction | Not yet recruiting | Phase 2 / Phase 3 | 2026-07-23 | NCT07721545 | |
| Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants | Neuralgia, Postherpetic, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, neuralgia, neuromuscular disease, peripheral nervous system disorder | Not yet recruiting | Phase 1 | 2026-06-01 | NCT07618715 | |
| Y-4 to Treat the Postherpetic Neuralgia | Neuralgia, Postherpetic, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, neuralgia, neuromuscular disease, peripheral nervous system disorder | Recruiting | Phase 2 | 2026-05-13 | NCT07275762 | |
| RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-09-30 | NCT07166380 | |
| Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects | Mild Hepatic Insufficiency; Moderate Hepatic Insufficiency; Normal Hepatic Function; Pharmacokinetic Differences; Saftey; Y-3 | Not yet recruiting | Phase 1 | 2025-07-08 | NCT07055412 | |
| Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Phase 3 | 2025-06-26 | NCT07040085 | |
| To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects | Healthy Male and Female Subjects | Recruiting | Phase 1 | 2025-06-10 | NCT07013773 | |
| Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject | Healthy Male and Female Subjects | Recruiting | Phase 1 | 2025-04-20 | NCT06935721 | |
| Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects | Healthy Adult Male and Female Volunteers | Recruiting | Phase 1 | 2025-04-20 | NCT06935682 |